Zoetis has completed an expansion of its global manufacturing and supply facility in Lincoln, Neb., to help meet the demand for SYNOVEX implants. The new 19,000 sq. ft., three-story facility will house the global manufacturing operations for SYNOVEX, which helps improve gain and feed efficiency in beef cattle.

"Enhancing our manufacturing capacity is an important step we have taken to make sure our customers know they can rely on us to bring them the high-quality SYNOVEX implants they have used for decades," Paul Parker, senior marketing manager with Zoetis, said. "Cattle performance is more important than ever in this era of high cattle prices, and SYNOVEX implants can help our customers maximize the productivity of their cattle."

Quality-control testing, validation of the manufacturing facility and building inventories of SYNOVEX formulations are now underway.

Zoetis added that it continues to invest in research and development of SYNOVEX. Last year, the Food & Drug Administration granted a label extension for SYNOVEX CHOICE for use in heifers.

In 2014, FDA completed an environmental impact review of SYNOVEX CHOICE, the first beef-cattle implant to receive such an assessment. FDA evaluated and approved data from in-depth environmental modeling studies completed by Zoetis, which examined exposure of the active ingredients in SYNOVEX CHOICE — trenbolone acetate and estradiol benzoate — and their metabolites. The studies also evaluated direct impact of these ingredients. FDA issued Zoetis a FONSI (finding of no significant impact) on the environmental assessment, including waterways, air, plants or aquatic species, when used according to label directions.